Cardiovascular Journal of Africa: Vol 22 No 3 (May/June 2011) - page 46

References: 1.
CRESTOR
®
package insert
2.
Jones P, Davidson MH, Stein EA,
et al
. Comparison of the Efficacy and Safety of Rosuvastatin Versus
Atorvastatin, Simvastatin, and Pravastatin Across Doses (STELLAR* Trial).
Am J Cardiol
2003;
92
:152-160.
3.
Schuster H, Barter PJ, Stender S,
et al
. Effects
of switching statins on achievement of lipid goals. Measuring Effective Reduction in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Am Heart
J
2004;
147
:705-712.
4.
Rosenson RS. Statins: can the new generation make an impresssion?
Expert Opin Emerg Drugs
2004;
9
(2):269-279.
5.
Shepherd J,
Hunninghake DB, Stein EA,
et al
. Safety of rosuvaststin.
Am J Cardiol
2004;
94
:882-888.
S4 CRESTOR
®
5 (Tablet)
Each CRESTOR
®
5 tablet contains 5 mg of rosuvastatin as rosuvastatin calcium.
S4 CRESTOR
®
10 (Tablet)
Each CRESTOR
®
10 tablet contains 10 mg of rosuvastatin as rosuvastatin calcium.
S4 CRESTOR
®
20 (Tablet)
Each CRESTOR
®
20 tablet contains 20 mg of rosuvastatin as rosuvastatin calcium.
S4 CRESTOR
®
40 (Tablet)
Each CRESTOR
®
40 tablet contains 40 mg of rosuvastatin as rosuvastatin calcium.
PHARMACOLOGICAL CLASSIFICATION:
A. 7.5 Serum-cholesterol reducers
INDICATIONS:
Primary hypercholesterolaemia, mixed dyslipidaemia and isolated hypertriglyceridaemia (including Fredrickson Type IIa, IIb and IV; and heterozygous familial hypercholesterolaemia) as an adjunct to diet when response to diet and exercise
is inadequate. Indicated in patients with homozygous familial hypercholesterolaemia, either alone or as an adjunct to diet and other lipid lowering treatments. CRESTOR
®
40 mg should only be considered in patients with severe hypercholesterolaemia and
high cardiovascular risk who do not achieve their treatment goal on 20 mg of CRESTOR
®
or alternative therapy. Specialist supervision is recommended when the 40 mg dose is initiated.
REGISTRATION NUMBERS:
CRESTOR
®
5: 41/7.5/0298, CRESTOR
®
10:
36/7.5/0349, CRESTOR
®
20: 36/7.5/0350, CRESTOR
®
40: 36/7.5/0351.
DETAILS OF THE REGISTERED LICENCE HOLDER:
AstraZeneca Pharmaceuticals (Pty) Ltd Reg No. 1992/005854/07. No. 5 Leeuwkop Road, Sunninghill, 2157, South Africa. Tel: 011
797 6000. Fax: 011 797 6001.
For full details relating to any information mentioned above please refer to the package insert of CRESTOR
®
5 mg, 10 mg, 20 mg and 40 mg. CRESTOR
®
is a registered trademark of AstraZeneca group.
Licensed from Shionogi & Co Ltd, Osaka, Japan. EPI Date: 13/05/2008. Date compiled: March 2011.
16162
Help your patients love themselves a little more.
CRESTOR
®
5 mg is suitable for select patients who need less aggressive lipid lowering
1
CRESTOR
®
is the more effective statin at lowering LDL-C and raising HDL-C
2
CRESTOR
®
10 mg will get most patients to LDL-C goal
1,3
CRESTOR
®
is well-tolerated and has a favourable benefit-risk profile
4,5
1...,36,37,38,39,40,41,42,43,44,45 47,48,49,50,51,52,53,54,55,56,...60
Powered by FlippingBook